Advanced in Attention Deficit Hyperactivity Disorder (ADHD)

Michael A. Van Ameringen

Hamilton, ON, CA 
Advanced in Attention Deficit Hyperactivity Disorder (ADHD)
Hamilton, ON, CA 
OverviewLocationsClinical Research

Overview

Michael Van Ameringen practices in Hamilton, Canada. Mr. Van Ameringen is rated as an Advanced expert by MediFind in the treatment of Attention Deficit Hyperactivity Disorder (ADHD). His top areas of expertise are Obsessive-Compulsive Disorder (OCD), Attention Deficit Hyperactivity Disorder (ADHD), Generalized Anxiety Disorder (GAD), and COVID-19.

His clinical research consists of co-authoring 103 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles and participated in 2 clinical trials in the study of Attention Deficit Hyperactivity Disorder (ADHD).

Gender
Male

Locations

Hamilton, ON, Canada
Other Locations
Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
Enrollment Status: Completed
Publish Date: October 26, 2023
Intervention Type: Drug
Study Drug: Methylphenidate Hydrochloride Controlled-Release Capsules
Study Phase: Phase 4
Recollect the Game: A Novel Treatment for Executive Functioning Deficits in Adults With ADHD
Recollect the Game: A Novel Treatment for Executive Functioning Deficits in Adults With ADHD
Enrollment Status: Active_not_recruiting
Publish Date: October 26, 2023
Intervention Type: Other
Study Phase: Not Applicable
Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study
Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study
Enrollment Status: Withdrawn
Publish Date: March 24, 2021
Intervention Type: Drug
Study Phase: Phase 3
Topiramate Augmentation to a Selective Serotonin Re-uptake Inhibitor (SSRI) in Treatment-Resistant Generalized Social Phobia: A Double-Blind Placebo -Controlled Trial.
Topiramate Augmentation to a Selective Serotonin Re-uptake Inhibitor (SSRI) in Treatment-Resistant Generalized Social Phobia: A Double-Blind Placebo -Controlled Trial.
Enrollment Status: Terminated
Publish Date: September 02, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Study of Topiramate Augmentation in Serotonin Reuptake Inhibitor (SRI) -Refractory Obsessive Compulsive Disorder
A Study of Topiramate Augmentation in Serotonin Reuptake Inhibitor (SRI) -Refractory Obsessive Compulsive Disorder
Enrollment Status: Completed
Publish Date: September 01, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder
A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder
Enrollment Status: Completed
Publish Date: June 18, 2019
Intervention Type: Drug
Study Phase: Phase 4
A Randomized Crossed-over Trial Examining Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) in Treatment Refractory Obsessive-Compulsive Disorder.
A Randomized Crossed-over Trial Examining Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) in Treatment Refractory Obsessive-Compulsive Disorder.
Enrollment Status: Withdrawn
Publish Date: June 18, 2019
Intervention Type: Device
Study Phase: Not Applicable
View 6 Less Clinical Trials

103 Total Publications

Corrigendum to "North American open-label 16-week trial of the MindShift smartphone app for adult anxiety" [J Mood Anxiety Disord 4C (2023) 100036].
Corrigendum to "North American open-label 16-week trial of the MindShift smartphone app for adult anxiety" [J Mood Anxiety Disord 4C (2023) 100036].
Journal: Journal of mood and anxiety disorders
Published: July 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Van Ameringen's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile